Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Utility of detection of telaprevir-resistant variants for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection.

Journal of clinical microbiology - 1 Jan 2014

Akuta Norio, Suzuki Fumitaka, Fukushima Taito, Kawamura Yusuke, Sezaki Hitomi, Suzuki Yoshiyuki, Hosaka Tetsuya, Kobayashi Masahiro, Hara Tasuku, Kobayashi Mariko, Saitoh Satoshi, Arase Yasuji, Ikeda Kenji, Kumada Hiromitsu

Abstract excerpt

The clinical usefulness of detecting telaprevir-resistant variants is unclear. Two hundred fifty-two Japanese patients infected with hepatitis C virus (HCV) genotype 1b received triple therapy with telaprevir-peginterferon (PEG-IFN)-ribavirin and were evaluated for telaprevir-resistant variants by direct sequencing at baseline and at the time of reelevation of the viral load. An analysis of the entire group...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Hepacivirus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C

Share to Interferons

Share to Oligopeptides

Share to Ribavirin

Share to RNA, Viral

Source

Open in PubMed Open full text

Identifiers

PMID: 24197875
DOI: 10.1128/JCM.02371-13
PMCID: PMC3911448

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Utility of detection of telaprevir-resistant variants for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection.PMID 24197875Read ↗

Prediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with hepatitis C virus genotype 1.Semantic proximity Read ↗

Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1.Semantic proximity Read ↗

Evolution of simeprevir-resistant variants over time by ultra-deep sequencing in HCV genotype 1b.Semantic proximity Read ↗

Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.Semantic proximity Read ↗

Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial.Semantic proximity Read ↗

Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1.Semantic proximity Read ↗

Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical TrialsSemantic proximity Read ↗

Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.Semantic proximity Read ↗

Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection.Semantic proximity Read ↗

Dynamic and rapid changes in viral quasispecies by UDPS in chronic hepatitis C patients receiving telaprevir-based therapy.Semantic proximity Read ↗

Telaprevir for retreatment of HCV infection.Semantic proximity Read ↗

Deep-Sequencing Analysis of the Gene Encoding the Hepatitis C Virus Nonstructural 3–4A Protease Confirms a Low Prevalence of Telaprevir-Resistant Variants at Baseline and the End of the REALIZE StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.